ClinicalTrials.gg
CompletedNCT03558087Updated Jun 27, 2024Results posted

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

A Phase 2 interventional study of Nivolumab and Gemcitabine in Bladder Cancer, sponsored by Matthew Galsky. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Matthew Galsky · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 10 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.

Enrollment
13th of 25
76 · median 76
Started
2018
with 5 others
Phase 2
13 of 25
1 open now
Registered
12th of 25
by date

Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 13th largest by enrollment, is one of 6 that started in 2018, is one of 13 in phase 2, and was the 12th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing nivolumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.

03

Conditions studied

  • Bladder Cancer

Keywords

  • muscle-invasive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance Status of ≤ 1 within 28 days prior to registration.
  • Histological evidence of clinically localized muscle-invasive urothelial cancer of the bladder (i.e., ct2-4n0m0). candidate for cystectomy as per treating physician.
  • Demonstrate adequate organ function per listed criteria:
  • (ANC): ≥ 1.5 x 10\^9/L
  • (Hgb): ≥ 9 g/dL
  • : ≥ 100 x 10\^9/L
  • Calculated : Creatinine ≤ 1.5 or creatinine clearance ≥ 60 mL/min
  • : ≤ 1.5 × (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL)
  • (AST) : ≤ 3 × ULN
  • Alanine aminotransferase (ALT) : ≤ 3 × ULN
  • All subjects must have adequate identified at screening (i.e., at least 15 unstained slides or paraffin block). Subjects without available archival tissue must be discussed with the sponsor-investigator.
  • Women of must have a negative serum or urine pregnancy within 7 days prior to C1D1. NOTE: "Women of childbearing potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not . Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.

NOTE: Women of childbearing potential (WOCBP) receiving nivolumab must be willing to abstain from heterosexual intercourse or to use 2 forms of effective methods of from the time of to 5 months after the last dose of nivolumab or for the timeframe outlined per package insert for chemotherapy. This timeframe also applies to breastfeeding. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method. Male subjects capable of fathering a child that are sexually active with partners of childbearing potential must be willing to abstain from heterosexual intercourse or to use 2 forms of effective methods of contraception from the time of informed consent to the timeframe outlined per package insert for chemotherapy. Contraception is not required for nivolumab. The timeframes described in the previous 2 sentences apply to sperm donation. Two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with systemic chemotherapy for muscle-invasive urothelial cancer of the bladder
  • Active infection requiring systemic therapy
  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  • Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
  • Prior active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Subjects with active, known or suspected disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Subjects with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  • Grade ≥ 2 neuropathy ( version 4).
  • Prior radiation therapy for bladder cancer
  • Positive test for virus surface antigen (HBV sAg) or virus ribonucleic acid (RNA) or hepatitis C antibody (HCV antibody) indicating acute or chronic infection.
  • Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • Solid organ or stem cell transplant
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Gemcitabine, Cisplatin and Nivolumab

    Combination Therapy: Nivolumab 360mg IV, Gemcitabine 100mg/m\^2 IV ,Cisplatin 70mg/m\^2 IV for four 21-day cycles. At restaging, subjects with cT0 or cTa status may undergo cystectomy or continue maintenance Nivolumab 240mg IV for up to 8 14-day cycles. Subjects with \> cTa status will undergo cystectomy.

    Drug: Nivolumab · Drug: Gemcitabine · Drug: Cisplatin

Interventions

  • Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).

    Also known as: Opdivo

  • Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four 21-day cycles.

    Also known as: Gemzar

  • Cisplatin 70mg\^m2 will be administered on Day 1 for four 21-day cycles.

    Also known as: Platinol

06

What researchers measure

Primary outcomes

  1. Clinical Complete Response (CCR) Rate

    Clinical complete response rate will be defined as the percentage of patients who achieved cT0 or cTa disease after gemcitabine, cisplatin, plus nivolumab.

    Time frame: 24 months

  2. Predict Benefit From Treatment

    Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment.Benefit will be defined as a pathologic complete response (\<pT1) in patients undergoing cystectomy and 2 year metastasis-free in patients pursuing surveillance. The positive predictive value of CCR with 95% confidence interval are presented in Outcome Measure Data Table. Positive predictive value is the ratio of patients truly diagnosed as positive to all those who had positive test results.

    Time frame: 24 months

Secondary outcomes

  1. Adverse Events

    The frequency and severity of all grade 3+ treatment-emergent adverse events occurring in at least 10% of patients are reported by CTCAEv4 term and grade.

    Time frame: AE had been recorded from time of signed informed consent until 100 days after discontinuation of study drug(s) or until a new anti-cancer treatment starts, whichever occurs first, up to a maximum of 13 months.

  2. Bladder Intact Overall Survival

    Bladder-intact overall survival is defined as the time from initiation of treatment until death or cystectomy.

    Time frame: Up to a maximum of 60 months

  3. Recurrence-free Survival

    Recurrence-free survival is defined as the time from initiation of treatment to death or recurrence, depending on which occurs first

    Time frame: Up to a maximum of 60 months

  4. Pathologic Complete Response Rate in Patients Undergoing Cystectomy

    Pathologic complete response rate in patients undergoing radical cystectomy is defined as the proportion of patients with \<pT1

    Time frame: Up to a maximum of 53 months

  5. Association Between a Prespecified Panel of Genomic Biomarkers and Benefit From Treatment in Patients Achieving a Clinical Complete Response.

    Benefit will be defined as a pathologic complete response (p\<T1) in patients undergoing cystectomy and 2 years metastasis-free in patients pursuing surveillance. The positive predictive value of CCR with or without genomic alterations in baseline TURBT tissue for a composite outcome measure of 2-year bladder-intact survival in patients forgoing immediate cystectomy or \<ypT1N0 in patients undergoing immediate cystectomy are presented with 95% confidence interval in Outcome Measure Data Table. Positive predictive value is the ratio of patients truly diagnosed as positive to all those who had positive test results.

    Time frame: 24 months

  6. Overall Survival

    Overall survival is defined as the time from initiation of treatment to death.

    Time frame: Up to a maximum of 60 months

07

Results

Posted Jun 27, 2024

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine, Cisplatin and Nivolumab
Started76
Completed76
Not completed0

Outcome measures

PrimaryClinical Complete Response (CCR) Rate

Clinical complete response rate will be defined as the percentage of patients who achieved cT0 or cTa disease after gemcitabine, cisplatin, plus nivolumab.

Time frame:
24 months
Reported as:
Number · Percentage of participants
Clinical Complete Response (CCR) Rate
Percentage of participantsGemcitabine, Cisplatin and Nivolumab
Clinical Complete Response (CCR) Rate43 (32 to 55)
PrimaryPredict Benefit From Treatment

Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment.Benefit will be defined as a pathologic complete response (\<pT1) in patients undergoing cystectomy and 2 year metastasis-free in patients pursuing surveillance. The positive predictive value of CCR with 95% confidence interval are presented in Outcome Measure Data Table. Positive predictive value is the ratio of patients truly diagnosed as positive to all those who had positive test results.

Time frame:
24 months
Reported as:
Number · Proportion of CCR patients
Predict Benefit From Treatment
Proportion of CCR patientsGemcitabine, Cisplatin and Nivolumab
Predict Benefit From Treatment0.97 (0.91 to 1)
SecondaryAdverse Events

The frequency and severity of all grade 3+ treatment-emergent adverse events occurring in at least 10% of patients are reported by CTCAEv4 term and grade.

Time frame:
AE had been recorded from time of signed informed consent until 100 days after discontinuation of study drug(s) or until a new anti-cancer treatment starts, whichever occurs first, up to a maximum of 13 months.
Reported as:
Number · participants
Adverse Events
participantsGemcitabine, Cisplatin and Nivolumab
ANEMIA12
NEUTROPHIL COUNT DECREASED26
URINARY TRACT INFECTION13
HYPONATREMIA5
HYPERTENSION4
WHITE BLOOD CELL DECREASED3
PLATELET COUNT DECREASED4
HEMATURIA3
DYSPNEA1
VOMITING1
ABDOMINAL PAIN2
HYPOKALEMIA3
PAIN1
ASPARTATE AMINOTRANSFERASE INCREASED1
DEPRESSION1
ANXIETY1
HYPERGLYCEMIA2
SecondaryBladder Intact Overall Survival

Bladder-intact overall survival is defined as the time from initiation of treatment until death or cystectomy.

Time frame:
Up to a maximum of 60 months
Reported as:
Median · Months
Bladder Intact Overall Survival
MonthsGemcitabine, Cisplatin and Nivolumab
CCR PatientsNA (47.34 to NA)
Non-CCR Patients4.53 (4.24 to 4.93)
SecondaryRecurrence-free Survival

Recurrence-free survival is defined as the time from initiation of treatment to death or recurrence, depending on which occurs first

Time frame:
Up to a maximum of 60 months
Reported as:
Median · Months
Recurrence-free Survival
MonthsGemcitabine, Cisplatin and Nivolumab
CCR Patients51.52 (39.92 to NA)
Non-CCR PatientsNA (24.21 to NA)
SecondaryPathologic Complete Response Rate in Patients Undergoing Cystectomy

Pathologic complete response rate in patients undergoing radical cystectomy is defined as the proportion of patients with \<pT1

Time frame:
Up to a maximum of 53 months
Reported as:
Count of participants · Participants
Pathologic Complete Response Rate in Patients Undergoing Cystectomy
ParticipantsGemcitabine, Cisplatin and Nivolumab
CCR Patients1
Non-CCR Patients3
SecondaryAssociation Between a Prespecified Panel of Genomic Biomarkers and Benefit From Treatment in Patients Achieving a Clinical Complete Response.

Benefit will be defined as a pathologic complete response (p\<T1) in patients undergoing cystectomy and 2 years metastasis-free in patients pursuing surveillance. The positive predictive value of CCR with or without genomic alterations in baseline TURBT tissue for a composite outcome measure of 2-year bladder-intact survival in patients forgoing immediate cystectomy or \<ypT1N0 in patients undergoing immediate cystectomy are presented with 95% confidence interval in Outcome Measure Data Table. Positive predictive value is the ratio of patients truly diagnosed as positive to all those who had positive test results.

Time frame:
24 months
Reported as:
Number · Proportion of CCR patients
Association Between a Prespecified Panel of Genomic Biomarkers and Benefit From Treatment in Patients Achieving a Clinical Complete Response.
Proportion of CCR patientsGemcitabine, Cisplatin and Nivolumab
Association Between a Prespecified Panel of Genomic Biomarkers and Benefit From Treatment in Patients Achieving a Clinical Complete Response.0.72 (0.56 to 0.87)
SecondaryOverall Survival

Overall survival is defined as the time from initiation of treatment to death.

Time frame:
Up to a maximum of 60 months
Reported as:
Median · Months
Overall Survival
MonthsGemcitabine, Cisplatin and Nivolumab
CCR PatientsNA (NA to NA)
Non-CCR PatientsNA (41.49 to NA)

Adverse events

Collected over All-Cause Mortality was monitored up to a maximum of 60 months. Serious Adverse Events and Other (Not Including Serious) Adverse Events were monitored up to 13 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine, Cisplatin and Nivolumab13/76 (17.1%)40/76 (52.6%)76/76 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventGemcitabine, Cisplatin and Nivolumab
URINARY TRACT INFECTIONInfections and infestations10/76
ACUTE KIDNEY INJURYRenal and urinary disorders5/76
HYPONATREMIAMetabolism and nutrition disorders4/76
SEPSISInfections and infestations4/76
INFECTIONS AND INFESTATIONS - OTHER, SPECIFYInfections and infestations3/76
THROMBOEMBOLIC EVENTVascular disorders3/76
ABDOMINAL PAINGastrointestinal disorders2/76
ATRIAL FIBRILLATIONCardiac disorders2/76
RENAL AND URINARY DISORDERS - OTHER, SPECIFYRenal and urinary disorders2/76
ADRENAL INSUFFICIENCYEndocrine disorders1/76
Most frequent other events
Showing 10 of 170
Most frequent other events
EventGemcitabine, Cisplatin and Nivolumab
FATIGUEGeneral disorders54/76
ANEMIABlood and lymphatic system disorders52/76
NEUTROPHIL COUNT DECREASEDInvestigations52/76
NAUSEAGastrointestinal disorders43/76
CREATININE INCREASEDInvestigations36/76
CONSTIPATIONGastrointestinal disorders35/76
HYPERGLYCEMIAMetabolism and nutrition disorders32/76
WHITE BLOOD CELL DECREASEDInvestigations31/76
PLATELET COUNT DECREASEDInvestigations29/76
ANOREXIAMetabolism and nutrition disorders22/76

Baseline characteristics

Age, Continuous
Age, Continuous(years)Gemcitabine, Cisplatin and Nivolumab
Median69 (39 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine, Cisplatin and Nivolumab
Female16
Male60
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gemcitabine, Cisplatin and Nivolumab
American Indian or Alaska Native0
Asian9
Native Hawaiian or Other Pacific Islander0
Black or African American1
White58
More than one race0
Unknown or Not Reported8
Region of Enrollment
Region of Enrollment(participants)Gemcitabine, Cisplatin and Nivolumab
United States76
Clinical stage
Clinical stage(Participants)Gemcitabine, Cisplatin and Nivolumab
cT2N0M043
cT3N0M024
cT4N0M09
Histology
Histology(Participants)Gemcitabine, Cisplatin and Nivolumab
Urothelial Cancer (UC)57
UC with squamous7
UC with glandular2
UC with micropapillary6
UC with other variant4
08

Study locations

7 sites
  • City of Hope
    Duarte, California 91010, United States
  • Univerity of Southern California
    Los Angeles, California 90033, United States
  • Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
    New York, New York 10029, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Penn Medicine Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Huntsman Cancer Institute University of Utah
    Salt Lake City, Utah 84112, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Feb 2024, 67 months.

Results were first posted in Jun 2024, 4 months after primary completion.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's 67 months is above that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 15, 2018
StartActual
Jul 13, 2018
Primary completionActual
Feb 16, 2024
CompletionActual
Mar 7, 2024
Results first posted
Jun 27, 2024
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03558087
Lead sponsor
Matthew Galsky
Responsible party
Matthew Galsky (Sponsor-Investigator, Hoosier Cancer Research Network) — Sponsor-investigator
First posted
Jun 15, 2018
Start date
Jul 13, 2018
Primary completion
Feb 16, 2024
Completion
Mar 7, 2024
Results posted
Jun 27, 2024
Last update
Jun 27, 2024

Study contacts

Matthew Galsky, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Gemcitabine · Cisplatin

Start the discussion